Read more The Translational Readout #2 - Tumor Heterogeneity: Why Treatment Responses Differ

8 September 2026

Tumors of the same diagnosis can differ substantially in their biology. The same treatment may therefore work differently between patients – and even across cells within a single tumor.

Read more

Read more 🎉 𝟭𝟬 𝗬𝗲𝗮𝗿𝘀 𝗼𝗳 𝗩𝗶𝘁𝗿𝗼𝗦𝗰𝗮𝗻!

3 September 2026

Today we celebrate an exciting milestone: 10 years of VitroScan! Over the past decade, we have grown, learned, innovated, and taken important steps towards our mission of supporting better informed treatment decisions for cancer patients through ex vivo micro-tumor testing.

Read more

Read more VitroScan featured in news items on Dutch national radio and television!

3 September 2026

The items focused on the need for a national investment bank, as outlined in the Rapport Wennink, and on a broader question facing the Netherlands: how can we strengthen our long-term economic growth through innovation?

Read more

Read more Info Sheet ADC efficacy assessment

1 June 2026

Download our Info sheet on ADC efficacy assessment in VitroScan's ex vivo micro-tumor platform

Read more

Read more Info Sheet Bispecific antibody testing

1 June 2026

Download our Info sheet on bispecific antibody efficacy assessment in VitroScan's ex vivo micro-tumor platform

Read more

Read more Our latest publication at a glance!

1 June 2026

Download our Info sheet on the latest VitroScan publication highlighting the predictive value of our platform

Read more

Read more VitroScan at AACR 2026

8 April 2026

Download our poster: Ex vivo micro-tumor testing platform to characterize and predict patient-specific immunotherapy responses

Read more

Read more VitroScan at SITC 2025

5 November 2025

Download our poster: Ex vivo micro-tumor testing identifies patient-specific anti-tumor immune responses to T cell engager ubamatamab

Read more

Read more VitroScan at ENA 2025

22 October 2025

Download our poster: Bispecific antibody ubamatamab induces patient-specific anti-tumor immune responses in an ex vivo platform for ovarian cancer

Read more

Read more Koedoot et al., npj Precision Oncology, 2025

30 August 2025

Publication of our study showing that VitroScan's 3D ex vivo micro-tumor testing platform can accurately predict whether an ovarian cancer patient will respond to chemotherapy.

Read more